Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic

by Toby Pepperrell, Andrew Hill, Michelle Moorhouse, Polly Clayden, Kaitlyn McCann, Simiso Sokhela, Celicia Serenata, Willem Daniel Francois Venter
Published 2020-04-01

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

by Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak
Published 2018-04-01

Are new antiretroviral treatments increasing the risks of clinical obesity?

by Andrew Hill, Laura Waters, Anton Pozniak
Published 2019-01-01

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients

by Isaac Aloysius, Anna Savage, Jey Zdravkov, Roxanna Korologou-Linden, Andrew Hill, Rachel Smith, Vicky Houghton-Price, Marta Boffito, Nneka Nwokolo
Published 2017-10-01

Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries

by Joe Kempton, Andrew Hill, Jacob A. Levi, Katherine Heath, Anton Pozniak
Published 2019-04-01

The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries

by Jacob Levi, Anton Pozniak, Katherine Heath, Andrew Hill
Published 2018-04-01